

2014

Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials

Taishiro Kishimoto
Northwell Health

A. Robenzadeh
Northwell Health

C. Leucht

S. Leucht

K. Watanabe

See next page for additional authors

Follow this and additional works at: <https://academicworks.medicine.hofstra.edu/articles>

 Part of the [Medical Molecular Biology Commons](#), and the [Psychiatry Commons](#)

Recommended Citation

Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane J, Correll C. Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials. . 2014 Jan 01; 40(1):Article 1053 [p.]. Available from: <https://academicworks.medicine.hofstra.edu/articles/1053>. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works.

Authors

Taishiro Kishimoto, A. Robenzadeh, C. Leucht, S. Leucht, K. Watanabe, M. Mimura, M. Borenstein, John Kane, and Christoph Correll

Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials

Taishiro Kishimoto^{1,2}, Alfred Robenzadeh¹, Claudia Leucht³, Stefan Leucht³, Koichiro Watanabe^{2,4}, Masaru Mimura², Michael Borenstein⁵, John M. Kane^{1,6,7,8}, and Christoph U. Correll^{*1,6,7,8}

¹The Zucker Hillside Hospital, Psychiatry Research, North Shore – Long Island Jewish Health System, Glen Oaks, NY; ²Keio University School of Medicine, Neuropsychiatry, Shinjuku-ku, Tokyo, Japan; ³Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universität München, München, Germany; ⁴Kyorin University School of Medicine, Neuropsychiatry, Mitaka, Tokyo, Japan; ⁵Biostat, Inc, Englewood, NJ; ⁶Hofstra North Shore LIJ School of Medicine, Department of Psychiatry and Molecular Medicine, Hempstead, NY; ⁷Albert Einstein College of Medicine, Department of Psychiatry and Behavioral Sciences, Bronx, NY; ⁸The Feinstein Institute for Medical Research, Manhasset, NY

*To whom correspondence should be addressed; Division of Psychiatry Research, the Zucker Hillside Hospital, 75-59 263rd Street, Glen Oaks, NY 11004, US; tel: (718) 470-4812, fax: (718) 343-1659, e-mail: ccorrell@lij.edu

Results from this study were presented at the Schizophrenia International Research Society 3rd biennial meeting, April 14–18, Florence, Italy, and the NCDEU 52nd Annual meeting, May 29–June 1, 2012 Arizona, USA.

Background: While long-acting injectable antipsychotics (LAIs) are hoped to reduce high relapse rates in schizophrenia, recent randomized controlled trials (RCTs) challenged the benefits of LAIs over oral antipsychotics (OAPs). **Methods:** Systematic review/meta-analysis of RCTs that lasted ≥ 6 months comparing LAIs and OAPs. Primary outcome was study-defined relapse at the longest time point; secondary outcomes included relapse at 3, 6, 12, 18, and 24 months, all-cause discontinuation, discontinuation due to adverse events, drug inefficacy (ie, relapse + discontinuation due to inefficacy), hospitalization, and nonadherence. **Results:** Across 21 RCTs ($n = 5176$), LAIs were similar to OAPs for relapse prevention at the longest time point (studies = 21, $n = 4950$, relative risk [RR] = 0.93, 95% confidence interval [CI]: 0.80–1.08, $P = .35$). The finding was confirmed restricting the analysis to outpatient studies lasting ≥ 1 year (studies = 12, RR = 0.93, 95% CI: 0.71–1.07, $P = .31$). However, studies using first-generation antipsychotic (FGA)-LAIs (studies = 10, RR = 0.82, 95% CI: 0.69–0.97, $P = .02$) and those published ≤ 1991 (consisting exclusively of all 8 fluphenazine-LAI studies; RR = 0.79, 95% CI: 0.65–0.96, $P = 0.02$) were superior to OAPs regarding the primary outcome. Pooled LAIs also did not separate from OAPs regarding any secondary outcomes. Again, studies using FGA-LAIs and those published ≤ 1991 were associated with LAI superiority over OAPs, eg, hospitalization and drug inefficacy. **Conclusions:** In RCTs, which are less representative of real-world patients than naturalistic studies, pooled LAIs did not reduce relapse compared with OAPs in schizophrenia patients. The exceptions

were FGA-LAIs, mostly consisting of fluphenazine-LAI studies, which were all conducted through 1991. Because this finding is vulnerable to a cohort bias, studies comparing FGA-LAI vs second-generation antipsychotics-LAI and LAI vs OAP RCTs in real-world patients are needed.

Key words: antipsychotics/adherence/depot/long-acting injection/meta-analysis/relapse/schizophrenia/treatment discontinuation

Introduction

Because psychopathology and social functioning can worsen with repeated psychotic episodes in patients with schizophrenia,^{1,2} relapse prevention is critical. There is strong evidence of antipsychotic efficacy for relapse prevention in chronic and first-episode patients,^{3,4} in that the risk of relapse is 2–6 times higher without medication.^{3–6} However, because nonadherence rates as high as 50% can limit the efficacy of pharmacotherapy,^{7,8} the use of long-acting injectable antipsychotics (LAIs) is an important option.⁹ In practice, patients and clinicians are sometimes reluctant to use LAIs because of stigma, needle pain, time constraints, side effect concerns, and cost.¹⁰ Given these drawbacks to the use of LAIs, convincing data showing the superiority of LAI over oral antipsychotics (OAPs) is needed to support the use of LAIs. The first LAI was introduced in the 1960s. Since then, at least 5 first-generation antipsychotics (FGAs)-LAIs and 3 second-generation antipsychotics (SGA)-LAIs have become available. Our previous meta-analysis found

that LAIs were associated with significantly lower relapse rates than OAPs.¹¹ However, new, large, controlled trials showed no benefit of LAIs.^{12–15} We performed a meta-analysis that incorporated the new randomized controlled trials (RCTs) and also applied broader inclusion criteria. The new analyses are based on twice as many studies and 3 times as many patients as compared with the earlier ones.

Method

The meta-analysis was performed following PRISMA guidelines.¹⁶

Search

We conducted a search without language restrictions, using MEDLINE/PubMed, Cochrane library, PsycINFO and CINAHL (last search: 06/2012), for RCTs of relapse prevention or maintenance treatment in schizophrenia and related disorders lasting ≥ 6 months. To avoid publication bias, we also included unpublished studies, such as conference proceedings and clinical trial registries (<http://clinicaltrials.gov/>). Search terms included synonyms of (1) antipsychotic(s); (2) schizophrenia and related disorders, (3) randomized; and (4) depot, (long-acting) injection(s), microsphere, decanoate, palmitate, enanthate. The electronic search was supplemented by hand search of reference lists of relevant publications. At least 2 independent investigators (TK, AR, CL) conducted the literature search.

Inclusion Criteria

We included randomized, head-to-head comparisons of LAI vs OAP for relapse prevention or maintenance treatment in schizophrenia. Patients in studies had to be ≥ 17 years old and have diagnoses of schizophrenia or schizoaffective disorder according to study diagnoses, but we included studies having other diagnoses, such as schizophreniform disorder, if schizophrenia or schizoaffective disorder were the vast majority of the study population. We included studies with a duration of at least 24 weeks and that provided information about relapse-related information, such as study-defined relapse or rehospitalization. We excluded penfluridol, a once-weekly OAP, considering it neither a LAI nor OAP.

Data Extraction and Outcomes

Data were extracted independently by ≥ 2 reviewers (TK, AR, CL, SL, CC). Authors and companies were contacted to provide missing information and unpublished data. Any disagreements were resolved by discussion.

The primary outcome was study-defined relapse at the latest point of follow-up. Where possible, the relapse rate was based on survival curves (which estimate relapse and take account of dropouts), but in other cases, relapse was based on the initial number of patients at risk. In those

cases where the paper did not define relapse, we used the next most-appropriate outcome, typically hospitalization or psychotic exacerbation (table 1).

Secondary outcomes included relapse at 3, 6, 12, 18, and 24 months, all-cause discontinuation, discontinuation due to adverse events, drug inefficacy (defined as relapse + discontinuation due to inefficacy; or defined as relapse when the overlap with discontinuation due to inefficacy was unclear), hospitalization, and nonadherence (defined as discontinuation due to nonadherence or study-defined nonadherence; see online [supplementary figure 10](#)).

Data Analysis

We used 2 population sets: (1) the “randomized” or “intent-to-treat” (ITT) population, where patients who dropped out due to group assignment are included in the analysis and (2) the “safety and/or efficacy” population, which includes only those patients who took ≥ 1 dose and received at least one postbaseline assessment. In contrast to our previous report where the randomized sample was primary, in this analysis the safety/efficacy population was primary, while the randomized population was examined in secondary analyses. All outcomes were dichotomous. The comparison of LAI vs OAP was performed (1) for each LAI individually (fluphenazine, risperidone, etc) and (2) across all pooled LAIs. In each analysis, we computed the pooled RR with its 95% confidence interval (CI) using the random-effects model.¹⁷ Number-needed-to-treat (NNT) was calculated where appropriate. With regard to the heterogeneity, τ^2 , I^2 , Q , and P -values are reported.

In addition to the primary and secondary outcome analyses, we conducted a series of subgroup/sensitivity analyses. In order to assess the robustness of the primary outcome, we repeated the analyses using relapse rates based on the initial sample size (where available, as well as exclusively), whereas the primary analysis employed relapse rates based on survival curves (where available, as well as exclusively). While the primary analysis was based on the full set of studies, we also conducted analyses on subgroups (identified a priori) of studies in order to identify potential methodological biases or different populations. These included subgroups based on (1) medication group (FGA-LAI vs SGA-LAI), (2) publication year (older RCTs [published ≤ 1991] vs newer RCTs [published ≥ 2005]); there was a 14 year gap between the last study published in 1991 and the next study published in 2005, (3) treatment concealment (double-blind double-dummy vs rater-masked vs open label), (4) in-/outpatient status (outpatients at baseline or shortly after initiation of antipsychotic treatment vs mixed patient status [in-/outpatients mixed or inpatients throughout the study]), (5) study duration (≥ 1 year vs < 1 year), and (6) medication allocation (same vs different antipsychotics in LAI and OAP arm). Finally, we also reexamined the results with the same inclusion criteria applied in the previous, more restricted meta-analysis,¹¹ ie, outpatient studies lasting ≥ 1 year.

Table 1. Description of Included Studies

Study/Country	n ^a	Study Design	Duration (wks)	Inclusion Criteria	Definition of Relapse-Related Outcome	Mean Age (Range) (y.o.)	% Male	% Hp at Baseline	Information Regarding Chronicity (# Hp, Duration of illness etc.)	Medication	Randomized #	Safety/ Efficacy #	Mean Dose (Range)
First-generation antipsychotic LAIs													
Fulphenazine depot													
Crawford and Forrest ⁴⁵	74/UK	31	DBDD	40	Stable and cooperative OPs with SCZ who are adherent to medication and attending the clinic	Withdrawal ^b : termination of the trial due to significant Sx that warranted unblinding the treatment in order to inform future Pt management	NR (20–65)	29	0	NR	14	14	NR (Same dose as before the trial) 10mg/d (fixed)
Del Giudice et al. ²⁵													
75/USA	88	DBDD/ RM ^c	69	IPs with SCZ who responded to oral FPZ and were discharged	Re-Hp ^b	NR (20–50)	100	0	48.8% had 5–10 Hps in the past	FPZ	27	27	25 mg/2 wks (fixed) 21.7 mg (5–80 mg)
Rifkin et al. ²⁷													
77/USA	73 ^d	DBDD	52	Stable OPs ^c on FPZ depot or oral for 4 wks, no more than minor side effects, cooperative and compliant	Relapse: clinical deterioration with marked social impairment	23.7 (17–38)	67	0	Mean # of Hps in the past: 1.79	FPZ decanoate	23	23	NR (0.5–2 ml/ 2-wks) NR (5–20 mg)
Falloon et al. ²⁶													
78/UK	53	DBDD	52	SCZ Pts returning to the community following Hp of an acute schizophrenic episode	Relapse: reappearance or exacerbation of schizophrenic features that led to withdrawal from the trial, regardless of re-Hp	39 (17–60)	45	0	81% had ≥2 Hps in the past	FPZ decanoate	NR	20	25 mg/2 wks ^f (flexible) 8 mg/d ^f (flexible)

Table 1. Continued

Study/Country	n ^a	Study Design	Duration (wks)	Inclusion Criteria	Definition of Relapse-Related Outcome	Mean Age (Range) (y.o.)	% Male	% Hp at Baseline	Information Regarding Chronicity (# Hp, Duration of illness etc.)	Medication	Randomized #	Safety/Efficacy #	Mean Dose (Range)
Hogarty et al. ⁴⁶ 79/USA	105	DBDD	104	Pts with SCZ who received major neuroleptic treatment during the Hp and was discharged	Relapse: unequivocal clinical deterioration of such magnitude that Hp appeared imminent after all reasonable attempts to maintain Pts with study medication failed or suicide Relapse: deterioration that could not be managed satisfactorily after adjustment of dosage within protocol limits	34.2 (18–55)	46	0	88% had ≥1 Hp in the past	FPZ decanoate FPZ	55 50	55 50	34 mg/2 wks (12.5–125 mg/2 wks) 9.9 mg/d (2.5–40 mg/d)
Schooler et al. ⁴³ 80/USA	290	DBDD	52	Pts with SCZ discharged after acute phase treatment and being treated in community	Relapse: deterioration that could not be managed satisfactorily after adjustment of dosage within protocol limits	29 (18–55)	59	100/0 ^e	100% newly Hp	FPZ decanoate	143	107 ^h	34.2 mg/3 wks (12.5–100 mg/3 wks) 24.8 mg/d (2.5–60 mg/d)
Barnes et al. ⁴⁷ 83/UK	36	DBDD	52	OPs with SCZ (PSE) regularly receiving depot FPZ for ≥6 months, and willing to participate the trial	Relapse: marked exacerbation of psychotic features requiring increase medication and re-Hp	49.5 (NR) ⁱ	50	0	≥77.8% have social performance limitations	FPZ decanoate Pimozide	19 17	19 17	NR (same dose as before the trial) NR (dose equivalent before the trial)
Kaneno et al. ⁴⁸ 91/Japan	263	DBDD	24	Chronic Pts with SCZ who need long-term treatment	Treatment discontinuation due to worsening of psychiatric Sx ^b	NR (NR) ^j	65	NR	Duration of illness was ≥10 years in 81%	FPZ decanoate HAL	130 133	127 132	12.6–50 mg/4 wks ^f (–75 mg/4 wks) 3.1–12.0 mg/d ^f (–18 mg/d)

Table 1. Continued

Study/Country	n ^a	Study Design	Duration (wks)	Inclusion Criteria	Definition of Relapse-Related Outcome	Mean Age (Range) (y.o.)	% Male	% Hp at Baseline	Information Regarding Chronicity (# Hp, Duration of illness etc.)	Medication	Randomized #	Safety/ Efficacy #	Mean Dose (Range)
Haloperidol depot Glick et al. ⁴⁹	05/ 35	OL	48	OPs with SCZ or SzAD ^d (DSM-IV) who require long-term therapy	Pts who were no longer exacerbation free ^b	42.3 (NR)	80	0	Mean duration of illness: 16.5 years	HAL decanoate	14	10/9	170 mg/4 wks (200 mg/4 wks ^b)
Zuclopthixol depot Arango et al. ²⁴	06/ 46	RM	52	Pts with SCZ (DSM-IV) who had a violent episode in the previous year, with a score of at least 3 on the physical aggression subscale of the modified Overt Aggression Scale	Hp ^b	34.0 (NR)	83	0	NR	Zuclophen-thixol depot Zuclophen-thixol	26 20	26 20	233 mg/2 wks (NR) 35 mg/d (NR)
Second-generation antipsychotic-LAIs													
Olanzapine-LAI Kane et al. ¹³	10/ 1065 ^f	DBDD	24	Clinically stable Pts with SCZ (DSM-IV) defined as having OP status for ≥4 wks, with a BPRS-P ≤4 on the following items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content	Psychotic exacerbation ^b : (1) an increase of any BPRS-P to a score of >4, with an absolute increase ≥2 for the specific item, (2) increase of any BPRS-P to a score >4, with an absolute increase ≥4 on the positive subscale, (3) Hp as the result of worsening of positive psychotic Sx	38.9 (18–75)	65	0	Mean duration of illness: 13.3 years. 36.9% had ≥2 psychotic episodes or exacerbations in last 24 months	OLA-LAI	599	599	150 mg/2 wks, 405 mg/4 wks, 300 mg/2 wks (fixed) 14.3 mg/d (10, 15, 20 mg/d)

Table 1. Continued

Study/Country	n ^a	Study Design	Duration (wks)	Inclusion Criteria	Definition of Relapse-Related Outcome	Mean Age (Range) (y.o.)	% Male	% Hp at Baseline	Information Regarding Chronicity (# Hp, Duration of illness etc.)	Medication	Randomized #	Safety/ Efficacy #	Mean Dose (Range)
Detke et al. ⁵⁰ 11/International	524	OL	104	OPs with SCZ (DSM-IV) who had no acute Hp in the 8 wks prior to visit 1, PANSS-T < 70, CGI-S ≤ 4 at visit 1 and 2, but had ≥ 2 episode of clinical worsening in the past 2 years	Relapse: (1) Hp. (2) >25% increase in PANSS-T, including ≥25% increase including ≥10 points increase (3) ≥1 increase in CGI-S (4) deliberate self-injury or injury to others, (5) discontinuation from study because of worsening of Sx	40.9 (18-65)	67	0	Mean duration of illness: 14.7 years. Mean # of psychotic episode in last 24 months: 2.7	OLA LAI	264	264	386.6 mg/4 wks (15-405 mg/4 wks) 12.7 mg/d (5-20 mg/d)
Risperidone-LAI Keks et al. ⁵¹ 07/International	629 ^m	OL	53	IP/OPs with SCZ or SzAD ⁿ (DSM-IV) who had acute exacerbation (Hp or requiring medical intervention) in the past 2 months, and had an additional acute exacerbation in the past 2 years, PANSS-T ≥ 50, BMI ≤ 40	Significant deterioration b): 1) Hp for Sx exacerbation, 2) need for an increased level of care and ≥ 2 points increase in CGI-S over 2 wks, 3) self-injury, suicidal/homicidal ideation or violent behavior	35.2 (≥18)	57	44	Mean duration of illness: 8.6 years	RIS-LAI	253	247	40.7 mg/2 wks (25, 50 mg/2 wks) 14.6 mg/d (5-20 mg/d)

Table 1. Continued

Study/Country	n ^a	Study Design	Duration (wks)	Inclusion Criteria	Definition of Relapse-Related Outcome	Mean Age (Range) (y.o.)	% Male	% Hp at Baseline	Information Regarding Chronicity (# Hp, Duration of illness etc.)	Medication	Randomized #	Safety/ Efficacy #	Mean Dose (Range)
Bai et al. ²³ 07/Taiwan	50	RM	48	Symptomatically stable SCZ (DSM-IV) and have been on oral RIS for ≥3 months, PANSS-T <80, PANSS conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content are all <4, CGI-I screening visit and baseline were same	Relapse: definition not given	46.4 (18–65)	50	100 ^c	Mean duration of Hop stay: 127.9 months	RIS LAI	25	23 ^p	Equivalent to oral 5.0 mg/d (25, 37.5, 50 mg/2 wks) ^q 4.0 mg/d (Same dose as before the trial)
Potapov et al. ⁵² 08/Russia	41	OL	52	Ops with SCZ (ICD-10) whose PANSS-T ≥60	Relapse: ≥5 increase in CGI-S and ≥20% in PANSS-T compared with previous assessment	34.9 (18–65)	58	0	NR	RIS LAI	20	20	41.7 mg/2 wks (NR)
Kamijima et al. ³⁸ NCT00240708 ³⁷ 09/Japan	205	OL	24	IP/OPs with SCZ (DSM-IV) who are taking RIS ≤6 mg/d with no change in dose for 28 days, PANSS-T ≥60–<120	Treatment discontinuation due to worsening of psychiatric Sx ^b	42.7 (≥20)	62	28	Mean duration of illness: 14.9 years	RIS LAI	153	147	32.3 mg/2 wks (25, 37.5, 50 mg/2 wks) 3.4 mg/d (2–6 mg/d)

Table 1. Continued

Study/Country	n ^a	Study Design	Duration (wks)	Inclusion Criteria	Definition of Relapse-Related Outcome	Mean Age (Range) (y.o.)	% Male	% Hp at Baseline	Information Regarding Chronicity (# Hp, Duration of illness etc.)	Medication	Randomized #	Safety/Efficacy #	Mean Dose (Range)
Gaebel et al. ⁵³ 10, de Arce Cordon et al. 12/ International	710 ^r	OL	104	Symptomatically stable IP/OPs with SCZ or SzAD ^b (DSM-IV) using stable dose of RIS ≤ 6 mg/d, OLA ≤ 20 mg/d, or FGA ≤ 10 mg/d HAL equivalent for ≥4 weeks and living in the same residence for ≥30 days, who were candidates for switching Tx.	Relapse: (1) psychiatric Hp, (2) increase in level of care and ≥25% PANSS-T increase, including ≥10 points increase, (3) deliberate self-injury, (4) clinically significant suicidal/homicidal ideation, (5) violent behavior resulting in significant injury to another person or property, (6) significant clinical deterioration defined as a CGI-C ≥6, (7) exceeding registered drug dose	41.6 (≥18)	58	NR	Mean duration of illness: 10.0 years. Mean # of Hps in the past: 5.3	RIS LAI	355	329/327	33.6 mg/2 wks (up to 50 mg/2 wks)
										QUE, ARI	401 ^r	382/371 ^p	QUE: 413.4 mg/d (up to 750 mg/d), ARI: 15.1 mg/d (10–30 mg/d)

Table 1. Continued

Study/Country	n ^a	Study Design	Duration (wks)	Inclusion Criteria	Definition of Relapse-Related Outcome	Mean Age (Range) (y.o.)	% Male	% Hp at Baseline	Information Regarding Chronicity (# Hp, Duration of illness etc.)	Medication	Randomized #	Safety/ Efficacy #	Mean Dose (Range)
Macfadden et al. ¹⁴ 10/International	355	RM	104	Pts with SCZ (DSM-IV) who experienced at least 2 psychotic relapses in the past 2 years, and have been stabilized for ≥2 months	Relapse: determined by masked monitoring board; (1) worsening of psychiatric Sx (Hp or significant increases in level of psychiatric care), (2) an increase of ≥25% PANSS-T, including ≥10 points increase from baseline, and CGI-C ≥6 with CGI-S of ≥4, (3) deliberate self-injury, clinically significant suicidal/homicidal ideation, or violent behavior, (4) drug discontinuation or addition of another AP for >1 wk because of lack of efficacy, (6) increase in dosage beyond the recommended dosage	37.9 (>18)	60	0	Mean duration of illness: 9.9 years —	RIS LAI ARI	179 176	179/177 176/172	41.8 mg/2 wks (25–50 mg/2 wks) 19.9 mg/d (10–30 mg/d)

Table 1. Continued

Study/Country	n ^a	Study Design	Duration (wks)	Inclusion Criteria	Definition of Relapse-Related Outcome	Mean Age (Range) (y.o.)	% Male	% Hp at Baseline	Information Regarding Chronicity (# Hp, Duration of illness etc.)	Medication	Randomized #	Safety/Efficacy #	Mean Dose (Range)
NCT00246259 ⁴⁴ 11/Canada	85	OL	104	IPs or OPs with SCZ, SzAD or schizophreniform disorder ^d (DSM-IV) with early onset (≤3 years), PANSS-T ≥60 and ≤120, currently on monotherapy atypical AP below RIS = 6, OLA = 20, QUE = 800 mg/d or treatment naïve. Pts stable within 18 wks entered the maintenance phase	Relapse: (1) psychiatric Hp; (2) psychiatric care increase and 25% increase in PANSS-T, including ≥10 points increase; (3) self-injury, suicidal, homicidal ideation, violence; and (4) CGI-C ≥6	22.7 (18–30)	84	NR	Mean duration of illness: 2.1 years	RIS LAI	44	42/32 ^g	NR (25–50 mg/2 wks) ^u NR (flexible dose)
Rosenheck et al. ¹² 11/USA	382	RM	104	Pts with SCZ or SzAD who are at risk of Hp as evidenced by current psychiatric Hp, Hp in the previous 2 years, or increased use of mental health services to prevent relapse	Hp ^b	51.0 (≥18)	91	40	Mean duration of illness: 23.4 years	RIS LAI	190	187	40.9 mg/1.5 wks (25, 37.5, 50 mg/2 wks) NR (flexible)
Schooler et al. ¹⁵ 11/USA	305	RM	74–130 ^v	OPs with SCZ or SzAD (32%) who had exacerbation within 12 months, CGI ≥ 4, in community ≥4 wks, ≥1 month since the most recent exacerbation	Relapse: determined by masked committee; Hp for psychosis, increases in level of care required to avoid Hp, substantial clinical deterioration measured by BPRS psychosis cluster, deliberate self-injury or violent behavior	38.2 (18–65)	71	NR ^w	Mean duration of illness: 15.9 years. Mean # of Hps in the past: 11.0	Any OAP except CLO	192	146	33.6 mg/2 wks (12.5–75 mg/2 wks) NR (flexible)

Notes: AP, antipsychotics, BMI, body mass index; BPRS-P, brief psychiatric rating scale positive item; CGI-C, clinical global impression change score; CGI-S, clinical global impression severity score; CLO, clozapine; DBDD, double-blind double-dummy; Dx, diagnosis; FPZ, fluphenazine; HAL, haloperidol; Hp, hospitalization; IP, inpatient; LAI, long acting injection; NR, not reported; OAP, oral antipsychotic; OL, open label; OLA, Olanzapine; OP, outpatient; PANSS, positive and negative symptom scale total score; PSE, present state examination; Pt, patient; QUE, quetiapine; RIS, risperidone; RM, rater masked; SCZ, schizophrenia; SGA, second-generation antipsychotics; Sx, symptom; SzAD, schizoaffective disorder; Tx, therapy.

^aOriginal study sample size.

^bStudy-defined relapse-related outcomes used in place of relapse.

^cRaters were masked for 3 arms, but DBDD were applied to 2 arms.

^dPts allocated to placebo arm are not included in the analysis.

^e100% Schizophrenia by clinical diagnosis but included 15% non-schizophrenia when assessed by research psychiatrists.

^fMost common dosing.

^g100% during intensive treatment phase, 0% in maintenance phase.

^hPts entered maintenance phase are used in the safety/efficacy population analysis.

ⁱAge range was not reported but 90% of the Pts were between 30–59 years old.

^jRate not reported.

^kClinicians were instructed to target this dose.

^lVery low dose (OLA-LAI 45 mg/4 wks) group is not included in the analysis.

^mPts allocated to RIS LAI 75 mg/2 wks were excluded due to protocol change.

ⁿScAD = 17.3%.

^oAll the patients were required to be hospitalized throughout the trial.

^pTwo Pts were discharged due to stable condition and removed from the trial.

^qDepot dose based on prior oral dose.

^rIncluding exploratory arm (ARI), randomized: $n = 45$, efficacy: $n = 44$.

^sScAD = 17.7%.

^tScAD = 6.5%, schizophreniform = 3.9%.

^uStarted from 25 mg, but was increased by increments of 12.5 mg up to 50 mg corresponding to the symptoms.

^vFull study period ranged between 17–30 months depending on enrollment date.

^wOP study including some Pts that were briefly hospitalized initially.

In post-hoc analyses, we compared the chlorpromazine (CPZ) equivalents between the LAI arm and OAP arm in the following study groups in order to identify potential confounders: all studies, using the same or different antipsychotic in the LAI and OAP groups, FGA- or SGA-LAI studies, and older or newer studies. We also compared mean CPZ equivalents within each of the OAP and LAI arms between FGA- vs SGA-LAI studies and between older vs newer studies. Antipsychotic doses were converted to CPZ equivalents using published guidelines.^{18–20} For LAIs, we used the manufacturers' recommended equivalent for the depot to oral conversion for the same drug and then converted to oral CPZ equivalents.

Data were entered into a funnel graph (trial effect against trial size) to investigate the likelihood of overt publication bias.²¹ Data were double entered into Review Manager 5.1.4 (Cochrane Collaboration, <http://ims.cochrane.org/revman>).

Results

Search and Study Characteristic

We identified 21 RCTs with 5176 participants (see online [supplementary figure 1](#)). One study²² was excluded because it did not quantify the number of patients at risk but reported only completed cases.

The number of patients per study ranged from 31–921 (median: 105), and mean study duration was 66.4 ± 32.2 (range: 24–130) weeks; duration: <1year: studies = 4, ≥1year: studies = 17). Nine studies had a double-blind, double-dummy design, 5 were rater-masked, and 7 were open. There were 10 FGA-LAI and 11 SGA-LAI studies. The number of studies with each individual LAI were fluphenazine = 8, haloperidol = 1, zuclopenthixol = 1, risperidone = 9, olanzapine = 2. The number of the studies with each OAP were fluphenazine = 4, pimozide = 2, haloperidol = 1, trifluoperazine = 1, zuclopenthixol = 1, olanzapine = 4, quetiapine = 2, risperidone = 2, aripiprazole = 2, and previous medication/physicians' choice = 3. Eleven studies (52.4%) used different antipsychotics in the 2 arms. Thirteen studies (61.9%) included only outpatients, 2 (9.5%) included inpatients at baseline who were discharged shortly after study initiation,^{12,15} 1 (4.8%) required patients to be hospitalized throughout the trial,²³ while 5 (23.8%) provided insufficient information. Relapse definitions varied. In 9 studies (42.9%), relapse was not defined. In 3 of these, we used hospitalization rate as relapse^{12,24,25}; in the remaining 6, we utilized study-defined symptomatic worsening ([table 1](#)).

Relapse Rate at the Longest Study Time Point

Analyzing individual LAIs, fluphenazine-LAI showed significant superiority over OAPs (studies = 8, $n = 826$, RR = 0.79, 95% CI: 0.65–0.96, $P = .02$, $I^2 = 23\%$, NNT = 13), while the other LAIs were not significantly superior to OAPs (pooled RRs for each LAI ranged

from 0.99–1.28). When pooled together, the risk for LAIs was similar to the risk for OAPs (studies = 21, $n = 4950$, RR = 0.93, 95% CI: 0.80–1.08, $P = .35$). The risk ratio varied across studies ($\tau^2 = 0.05$, $I^2 = 58\%$, $Q = 47.31$, $df = 20$, $P = .0005$) ([figure 1](#)).

Relapse Rate at Specific Time Points

Comparing relapse rates at different time points (3, 6, 12, 18, and 24 months), pooled LAIs did not separate from OAPs (see online [supplementary figures 2, 3, 4, 5, 6](#)). A single study of fluphenazine depot yielded trend-level superiority at 18 months (study = 1, $n = 105$, RR = 0.66, 95% CI: 0.44–0.99, $P = .05$) and significant superiority at 24 months (study = 1, $n = 105$, RR = 0.56, 95% CI: 0.38–0.80, $P = .002$); 2 studies of olanzapine-LAI yielded trend-level inferiority at 6 months (studies = 2, $n = 1445$, RR = 1.27, 95% CI: 0.97–1.66, $P = .09$).

All-Cause Discontinuation

Neither individual LAI nor pooled LAIs separated from OAPs regarding all-cause discontinuation (pooled LAIs: studies = 21, $n = 4882$, RR = 1.00, 95% CI: 0.89–1.13, $P = .99$) ([figure 2](#)).

Discontinuation Due to Adverse Events

Neither individual nor pooled LAIs separated from OAPs regarding discontinuation due to adverse events in the safety/efficacy (pooled LAIs: studies = 19, $n = 4662$, RR = 1.10, 95% CI: 0.74–1.64, $P = .65$) (see online [supplementary figure 7](#)).

Drug Inefficacy

Among individual LAIs, only fluphenazine was superior to OAPs regarding drug inefficacy defined as relapse + discontinuation due to inefficacy (studies = 8, $n = 826$, RR = 0.78, 95% CI: 0.66–0.91, $P = .002$) in the safety/efficacy population. Conversely, olanzapine-LAI was inferior to OAP on this measure ($n = 1445$, RR = 1.52, 95% CI: 1.12–2.07, $P = .007$), but this was based on only 2 studies. Pooled LAIs did not separate from OAPs regarding drug inefficacy (see online [supplementary figure 8](#)).

Hospitalization

Among individual LAIs, only fluphenazine-LAI was superior to OAPs in preventing hospitalization (studies = 4, $n = 197$, RR = 0.82, 95% CI: 0.67–0.99, $P = .04$). Pooled LAIs showed trend-level superiority over OAPs (studies = 10, RR = 0.89, 95% CI: 0.78–1.02, $P = .09$) (see online [supplementary figure 9](#)).

Nonadherence

Only 2 studies utilized pill counts or urine concentration.^{26,27} One zuclopenthixol study yielded trend-level




Fig. 1. Relapse rate-estimated rate preferred, longest time point (safety/efficacy population).




Fig. 2. All-cause discontinuation (safety/efficacy population).

superiority regarding adherence (study = 1, $n = 46$, $RR = 0.26$, 95% CI: 0.06–1.14, $P = .07$). Pooled LAIs did not separate from OAPs (studies = 10, $n = 2018$, $RR = 0.77$, 95% CI: 0.49–1.22, $P = .22$; see online [supplementary figure 10](#)).

Sensitivity and Subgroup Analyses: Primary Outcome

Pooled LAIs did not separate from OAPs whether raw relapse rates were used preferentially over estimated relapse rates ($P = .49$), or whether only estimated rates ($P = .25$) or raw rates ($P = .48$) were used.

Nonsuperiority of LAIs over OAP remained in all clinically relevant subpopulations and treatment groups, ie, treatment concealment (double-blind, double-dummy vs rater-masked vs open label), in-/outpatient status, study duration (≥ 1 year, or < 1 year), using the same vs different medication in the LAI and OAP arm ([table 2](#)). When we repeated the analyses with more stringent inclusion criteria, which we had applied in our previous meta-analysis,¹¹ ie, outpatient study lasting ≥ 1 year, pooled LAIs again did not separate from OAPs (studies = 12, $n = 2162$, $RR = 0.93$, 95% CI: 0.71–1.07; [table 2](#)).

Analyzing FGA-LAIs and SGA-LAIs separately, FGA-LAIs were significantly superior to OAPs in preventing relapse (studies = 10, $n = 897$, $RR = 0.82$, 95% CI: 0.69–0.97, $P = .02$, $NNT = 15$). However, SGA-LAIs did not separate from OAPs (studies = 11, $n = 4053$, $RR = 1.00$, 95% CI: 0.81–1.23, $P = 1.0$; [figure 3](#)). Nevertheless, effect sizes for FGA-LAIs and SGA-LAIs were not significantly different from each other ($P = 0.14$). Furthermore, the superiority of FGA-LAIs, was moderated by publication year. In RCTs published until 1991 (studies = 8, $n = 826$, $RR = 0.79$, 95% CI: 0.65–0.96, $P = .02$, $I^2 = 23$, $NNT = 13$), consisting exclusively of all fluphenazine LAIs, LAIs were superior to OAPs. However, this was not the case in the newer RCTs published since 2005 (studies = 13, $n = 4124$, $RR = 1.01$, 95% CI: 0.83–1.22, $P = .94$), which included only 2/10 FGA-LAI studies; [figure 3](#)).

Subgroup Analyses: Secondary Outcome

Limiting the sensitivity analyses to variables that showed a significant effect on the treatment comparison, superiority of FGA-LAIs over OAPs but not of SGA-LAIs over OAPs was also apparent regarding some secondary outcomes, such as drug inefficacy or hospitalization. However, again, the results were moderated by publication year ([table 2](#)).

CPZ Dose Within and Across Studies

Only 13 of the 21 studies (61.9%) reported mean dose levels in both treatment arms. Converting antipsychotic doses to CPZ equivalents, we found no significant differences between LAI and OAP CPZ equivalents across

all studies (studies = 13, $P = .11$), within studies using the same antipsychotics in the LAI and OAP arms (studies = 8, $P = .95$), FGA-LAI studies (studies = 5, $P = .63$), SGA-LAI studies (studies = 8, $P = .15$), and older studies (studies = 3, $P = 1.0$). However, there was a trend-level difference for higher CPZ equivalents in OAP arms compared with LAI arms within studies using different antipsychotics (studies = 5, $P = .06$) and in newer studies (studies = 10, $P = .06$).

Comparing FGA- and SGA-LAI studies, there was a trend-level difference for higher CPZ equivalent doses in FGA-LAI studies in both LAI arms (15 treatment arms, $P = .08$) and OAP arms (14 treatment arms, $P = .08$). Moreover comparing older vs newer studies, CPZ equivalent doses were significantly higher both in the LAI arms (15 treatment arms, $P = .01$) and in the OAP arms (14 treatment arms, $P = .03$) of the older studies.

Randomized Population

Using the randomized population, the results did not change, except for few minor variations: fluphenazine-LAI showed trend level superiority over OAP regarding relapse at 3 months ($P = .06$) and at 12 months ($P = .08$), hospitalization for pooled LAIs did not reach statistical significance ($P = 0.14$), and double-blind double-dummy study design was associated with trend-level superiority of LAIs vs OAPs ($P = .09$).

Publication Bias

The symmetrical funnel-plot did not suggest overt publication bias (see online [supplementary figure 11](#)).

Discussion

To our knowledge, this is the largest meta-analysis comparing LAI vs OAP efficacy for relapse prevention in schizophrenia. Compared with our prior meta-analysis,¹¹ we broadened the inclusion criteria by incorporating studies that enrolled inpatients and outpatients, and also by including studies lasting 6 months to < 1 year. However, at the same time, we also examined the result within the studies meeting our previous inclusion criteria (outpatient study, lasting ≥ 1 year).

We found that pooled LAIs were not superior to OAPs in all of the examined relapse-related outcomes. The only exception was fluphenazine-LAI, which showed significant superiority over OAPs in several relapse-related outcomes. This lack of superiority of LAIs is in contrast to our previous meta-analysis,¹¹ which showed significant superiority of LAIs over OAPs in schizophrenia with a $NNT = 10$. However, this difference is not due to the use of broadened inclusion criteria for analyzed studies, as results were similar when the analyses were limited to the outpatient studies lasting ≥ 1 year. Rather, the nonsuperiority of LAIs vs OAPs

Table 2. Subgroup and Sensitivity Analysis in Safety/Efficacy Population

Variables	# Trials	n	Relative Risk				NNT
			RR	95% CI	P	F(%)	
Relapse rate							
Relapse rate calculation							
Using preferentially raw over estimated rates	21	4963	0.95	0.81, 1.11	0.49	55	NA
Using only estimated rates	12	3684	0.91	0.77, 1.07	0.25	71	NA
Using only raw rates	19	4605	0.94	0.78, 1.12	0.48	51	NA
Medication class							
FGA-LAIs	10	897	0.82	0.69, 0.97	0.02	15	NA
SGA-LAIs	11	4053	1.00	0.81, 1.23	0.99	70	NA
Publication year							
Older RCTs ≤1991	8	826	0.79	0.65, 0.96	0.02	23	12
Newer RCTs ≥2005	13	4124	1.01	0.83, 1.22	0.94	64	NA
Treatment concealment							
Double-blind double-dummy	9	1717	0.86	0.68, 1.09	0.21	45	NA
Rater-masked	5	1108	1.07	0.93, 1.23	0.34	9	NA
Open label	7	2095	0.91	0.64, 1.28	0.58	70	NA
In-/outpatient status at baseline							
Outpatient status	15	3137	0.95	0.83, 1.08	0.41	45	NA
Mixed patient status	6	1813	1.05	0.61, 1.79	0.86	69	NA
Study duration							
≥1 year	15	3470	0.91	0.77, 1.07	0.25	66	NA
<1 year	6	1480	1.14	0.82, 1.58	0.43	0	NA
Medication allocation							
Same AP in LAI and OAP arm	10	2544	0.92	0.78, 1.09	0.35	47	NA
Different AP in LAI and OAP arm	11	2406	0.94	0.71, 1.26	0.70	68	NA
Combination of categories							
Outpatient status + ≥1 year	12	2162	0.93	0.81, 1.07	0.31	48	NA
Drug inefficacy							
Medication class							
FGA-LAIs	10	897	0.80	0.69, 0.93	0.004	0	17
SGA-LAIs	11	4072	1.07	0.85, 1.36	0.55	70	NA
Publication year							
Older RCTs ≤1991	8	826	0.78	0.66, 0.91	0.002	0	15
Newer RCTs ≥2005	13	4143	1.07	0.87, 1.33	0.51	64	NA
Hospitalization							
Medication class							
FGA-LAIs	5	243	0.84	0.69, 1.01	0.07	0	NA
SGA-LAIs	5	2098	0.91	0.74, 1.12	0.37	29	NA
Publication year							
Older RCTs ≤1991	4	197	0.82	0.67, 0.99	0.04	0	9
Newer RCTs ≥2005	6	2144	0.93	0.77, 1.12	0.43	19	NA

Notes: AP, antipsychotics; FGA, first-generation antipsychotics; LAI, long-acting injection; NA, not applicable; NNT, number needed to treat; OAP, oral antipsychotics; SGA, second-generation antipsychotics; RCTs, randomized controlled trial. *P*-values <.05 bolded to indicate statistical significance.




Fig. 3. Subgroup analysis comparing (1) FGA-LAI studies published ≤1991, (2) FGA-LAI studies published ≥2005, (3) SGA-LAI studies published ≥2005.

When FGA-LAIs (combining the top two groups) and second-generation antipsychotics (SGA)-LAIs (bottom group) were analyzed separately, FGA-LAIs were significantly superior to OAPs in preventing relapse (Studies = 10, *n* = 897, RR = 0.82, 95% CI: 0.69–0.97, *P* = 0.02, NNT = 15, heterogeneity: τ^2 = 0.01, *I*² = 15%, *Q* = 10.62, df = 9, *P* = 0.30), but SGA-LAIs were not (Studies = 11, *n* = 4053, RR = 1.00, 95% CI: 0.81–1.23, *P* = 0.99, heterogeneity: τ^2 = 0.07, *I*² = 70%, *Q* = 32.93, df = 10, *P* = 0.0003). When older randomized controlled trials (RCTs) (<1991) (top group) and the remaining newer RCTs (>2005) (combining the bottom two groups) were analyzed separately, LAIs had lower relapse rates in older RCTs (Studies = 8, *n* = 826, RR = 0.79, 95% CI: 0.65–0.96, *P* = 0.02, NNT = 13, heterogeneity: τ^2 = 0.02, *I*² = 23%, *Q* = 9.06, df = 7, *P* = 0.25), but not in the remaining newer RCTs (Studies = 13, *n* = 4950, RR = 1.01, 95% CI: 0.83–1.08, *P* = 0.95, heterogeneity: τ^2 = 0.06, *I*² = 64%, *Q* = 33.39, df = 12, *P* = 0.0008).

in the extended analyses of our study was due to a shift in the RR toward the null hypothesis rather than due to increased imprecision indicated by a widening of the CI. In fact, the CI of our primary result was slightly narrower than in the prior meta-analysis (RR = 0.93 [95% CI: 0.80–1.08] vs RR = 0.70 [95% CI: 0.57–0.87]),

suggesting that the point estimate was, if anything, somewhat more precise.

On the other hand, we found in subgroup analyses that FGA-LAIs studies or older RCTs showed significant superiority of LAIs over OAPs but that this was not the case in SGA-LAIs studies or newer RCTs. (In a byline,

we note that the distinction between FGAs and SGAs is a questionable one.)²⁸ However these findings require cautionary interpretation. Eight out of 10 FGA-LAI studies were published by 1991, and all 8 RCTs published by 1991 employed exclusively fluphenazine-LAI. Hence, these distinctions were nearly equal, and it is impossible to disentangle the potential reasons for different effect sizes. Moreover, the subgroup analysis comparing the effect sizes of FGA-LAIs and SGA-LAIs relative to OAPs did not yield a significant difference, suggesting that in this indirect comparison, there was no indication that FGA-LAIs are superior to SGA-LAIs. That being said, we consider the following explanations for the differential findings for FGA-LAIs (or older RCTs). One possibility is publication bias. Because the registration system of clinical trials has been introduced, companies are obliged to either publish all studies or make the data publically available, while in earlier years, studies showing less advantages for LAIs may not have been published. Another possibility is changing definitions of relapse. In order to mitigate potential adverse consequences of participating in clinical trials, recent studies tended to utilize lower thresholds for relapse, which can increase the rate of false positives. From the definitions encountered in these analyses, this tendency was not obvious (see [table 1](#)). However, it is hard to rule out this possibility, as some older studies used vague definitions rather than quantitative measures, such as predefined changes in PANSS score. In addition to various definitions, thresholds used to determine relapse can also have a big impact. For example, hospitalization as threshold is susceptible to health insurance system variations, social supports, or clinician's judgment and can differ by geographical regions or over time. Furthermore, the OAPs used in FGA-LAI studies published until 1991 were FGAs, while OAPs used in SGA-LAI studies published since 2005 were generally SGAs. One can argue that patients allocated to FGA-OAPs might have a greater chance of relapse, either due to poorer adherence or differences in neuropharmacologic properties compared with SGA-OAPs. This could be consistent with our recent meta-analysis comparing oral SGAs and FGAs, which showed a small but significant superiority of SGAs in preventing relapse, but due to limited information, we could not determine whether nonadherence was a factor.²⁹ We examined this possibility in the current analyses as well, but we did not find significant group differences. However, adherence is rarely assessed directly, and the evaluations involving these outcomes are very crude, which is a major limitation of the available RCTs. LAIs are thought to be better via improved adherence, not via intrinsically better efficacy. Therefore, it is unclear whether LAIs were not superior because compliance with OAPs was good enough in the context of RCTs.

Regarding CPZ equivalent doses, there were some significant or trend-level differences within and across

studies. CPZ equivalents trended toward being higher in OAP arms compared with LAI arms within studies using different antipsychotics, which may have disadvantaged the LAI arms. However, in the studies that used the same medications in the LAI and OAP arm and used also similar CPZ equivalent doses in both arms, there was also no difference in terms of preventing relapse. In SGA-LAI studies, or newer studies, CPZ equivalent doses in the OAP arms also trended to be higher than in the LAI arms. In addition, CPZ equivalent dosages used in FGA-LAI studies and in older studies were at a trend level and significantly higher than in SGA-LAI studies and in newer studies, respectively. These findings are consistent with a trend toward using lower antipsychotic doses since the more widespread use of SGAs. Whether or not this difference is relevant for the superiority of FGA-LAIs and older studies that used higher doses in both the LAI and OAP arms than SGA-LAI and newer studies that used lower doses in both arms is unclear. However, it is possible that higher LAI doses were more effective in showing superiority over OAPs, which may have been dosed higher than necessary leading to dropout or non-adherence due to extrapyramidal side effects. However, the interpretability of the results of potential dose differences is limited by missing information on mean doses in the LAI and OAP arms, especially in old studies, and by substantial differences in the suggested conversion factors from antipsychotic doses to CPZ equivalents, both of which applied mostly to older studies using FGA-LAIs.

In contrast to our results, recent naturalistic studies support the advantages of LAIs over OAPs in relapse prevention³⁰⁻³² as do mirror image studies.^{33,34} Tiihonen et al.³¹ reported in a nationwide cohort that the risk of rehospitalization with LAIs was one-third that of OAPs. Most LAIs showed significant superiority compared with each OAP counterpart regarding all-cause discontinuation. These results are especially important given the potentially conservative bias in that the patients who receive doctor's choice LAIs are more likely to be non-adherent and more severely ill compared with patients receiving doctor's choice OAPs. Moreover, patients consenting to clinical trials of LAIs may not be representative of those prescribed LAIs in real-world settings.³⁵ Participants in clinical trials might overrepresent patients with better engagement with health care providers, better adherence to the treatment, lower illness severity, and better cognitive capabilities to understand complex issues. This difference in procedures can potentially lead to a cohort bias in that less severely ill patients could be enrolled in newer trials, particularly with increasing stringency of consent processes. This may explain the different results of older vs newer studies.

It is also important to recognize that participation in a controlled trial alters the ecology of treatment delivery and experience. Patients in clinical trials are likely to receive more and different types of attention than those

in routine care, from measures of adherence to reminders to attend clinical/research assessment sessions, or to the provision of free medication.³⁶ In addition, more frequent monitoring during a trial enables psychiatrists to change dosages according to the symptoms and provide supportive psychotherapy. It is difficult to determine what role these factors might have in altering patterns of medication-taking in contrast to routine care and to what extent they might, therefore, diminish the potential advantages of LAIs in RCTs. The substantial disparity between the large naturalistic cohort study results and those of RCTs in this context would support such concerns.

To this point, we have assumed that LAIs must be more effective than OAPs and have been trying to understand why this is not apparent in the RCTs. We should also consider the possibility that if patients are fully adherent with OAPs, the OAPs may actually be more efficacious than LAIs as suggested by 2 recent trials.^{23,37,38} One interesting hypothesis is the potential supersensitivity of the dopamine D2 receptor. Long-term, continuous D2 blockade may increase the number and/or high-affinity state of dopamine receptors.^{39,40} In addition, there are data suggesting that transient, rather than continuous blockade of D2 receptors by “extended dosing” (eg, every other day dosing), may be more efficacious in both animal and human studies.^{41,42} Therefore, LAIs might result in more continuous D2 blockade and receptor upregulation/supersensitivity compared with OAPs. This effect would be differentially stronger when the OAPs do not consist of high-potency FGAs, as oral SGAs generally have less complete or prolonged D2 blockade.

Regarding our study methodology, 2 points require consideration. First, we utilized relapse rate preferentially based on survival analyses as a primary outcome. We acknowledge that graphically calculated relapse rates from survival curves can result in higher relapse rates compared with raw rates because the denominator decreases as dropout occurs. On the other hand, raw relapse rates do not count the potential relapse among patients who dropped out. Moreover, in case of systematically different dropout rates between the treatment arms resulting in shorter follow-up periods in one treatment compared with another, a bias is introduced that disfavors the treatment with better acceptability and greater persistence, as more time is available for relapses to occur. For these reasons, we believe that estimated rates may yield more accurate data than raw relapse rates. However, we acknowledge the problem of using estimations, rather than observed data, and the mixing of estimated and raw rates from studies not providing survival curves. To deal with this problem, we analyzed the data in several ways, utilizing raw instead of estimated relapse rates, and using raw or estimated rates exclusively. The results remained the same, independent of how relapse rates were calculated.

Second, we used each the safety/efficacy and randomized population as denominators for the analyses.

While ITT analysis is the gold standard for clinical trials, ITT definitions varied, which is problematic. Some defined ITT as patients taking the medication at least once, or receiving at least one assessment (modified ITT), while others utilized the randomized population. Moreover, several studies provided survival curves and other results, which were solely based on the modified ITT sample, and 1 study²⁶ only presented the modified ITT population. It is widely accepted that the reluctance toward injections is an important obstacle for introducing LAIs.⁹ Some studies included in our analyses reported that patients dropped out when learning of their LAI allocation. We considered it important to include those patients as dropouts. However, given the fact that more studies provided data using modified ITT populations, we wanted to also examine the risk of relapse once patients are on LAIs. Therefore, we analyzed the results in both populations separately, which we considered the most conservative strategy, and there were no important differences.

Results of these analyses have to be interpreted in the context of several limitations. First, the database, though larger than in the previous meta-analysis, is still limited. For example, no long-term RCTs comparing paliperidone-LAI or aripiprazole-LAI with OAPs were available. Furthermore, relapse definitions varied. We utilized each study-defined relapse measure, and if no definition was available, we used the most-appropriate relapse-related outcome, ie, predominantly psychiatric hospitalization. The problem of heterogeneously defined relapse is not surprising because there is no universally accepted definition. On the other hand, this heterogeneity and broad-based definition could also serve to enhance the generalizability of the results. There was a 14-year gap between the last study published in 1991 and the next study published in 2005, which enabled us to examine the effect of time when the study was conducted. Because clinical and diagnostic concepts of the disease and therapeutic environments have changed over time, it is unclear, which factors in addition to the almost exclusive study of FGA-LAIs earlier and of SGA-LAIs later may have influenced the results. In addition, heterogeneity of the results was seen. Although the majority of studies targeted chronic patients with over 10 years of illness, some targeted patients with even longer illness duration,¹² while some targeted relatively early-onset patients.^{43,44} One study included patients with aggressive behavior,²⁴ another included patients who were hospitalized throughout the study.²³ Such clinical characteristics and different treatment settings may have caused heterogeneity. Of note, risperidone-LAI studies were found to be most heterogeneous ($\tau^2 = 0.09$, $I^2 = 74\%$, $Q = 30.92$, $df = 8$, $P = .0001$). Moreover, the reporting of drop out due to “adverse events” is not always unambiguously restricted to physiologic/physical adverse effects. Rather, at times, discontinuation due to potential inefficacy-related outcomes,

eg, anxiety, agitation, and worsening of psychosis, may be counted as a side effect-related discontinuation, which complicates the interpretation of this outcome.

Further limitations regarding the design of the analyzed studies include issues like treatment concealment (7/21 were open studies), in- vs outpatient status (6/21 included inpatients throughout the study, or presumably a significant portion of the study), study duration (6/21 were <1 year), and medication allocation (10/21 used different medications in the LAI and OAP arms). We consider the double-blind, double-dummy design favorable, as it reduces expectancy and rater biases. At the same time, however, this design itself is very different from clinical practice, and might have contributed to increased selection bias. Moreover, inpatient studies apparently ensured adherence, which may have strengthened the efficacy of the OAP arm. Because nonadherence can increase over time, one may expect also that the relative superiority of LAI compared with OAPs develops over time. Such an effect may explain the lower risk ratio in the longer term studies when we analyzed separately results from studies lasting <1 year (RR = 1.14, 95% CI: 0.82–1.58, $P = .43$) and those lasting ≥ 1 year (RR = 0.91, 95% CI: 0.77–1.07, $P = .25$). However, LAIs were not superior to OAPs in either study subgroup, and some recent studies with durations of ≥ 2 years^{12,14,15} also failed to show superiority of LAIs. This calls into question that the study duration is a major determinant. Using different medications in the oral and LAI arms makes it difficult to disentangle the independent efficacy of the delivery method from potential differences in the efficacy of the 2 drugs including inappropriate dose equivalency. We attempted to examine these issues by subgroup analyses, which all yielded the same result of similar outcomes in the LAI and OAP groups.

In conclusion, while we had anticipated that LAIs (with their intrinsically better adherence) would be more effective than OAPs in preventing relapse, this was not evident in a synthesis of the available RCTs. Notably, these results are in contrast to naturalistic cohort studies showing superiority of LAIs in preventing rehospitalization. Further consideration is required to understand the reasons for this discrepancy. In order to evaluate the real-world effectiveness of LAIs compared with OAPs, large and long pragmatic trials are needed, which better resemble common clinical practice.

In our analysis, FGA-LAIs, but not SGA-LAIs, outperformed OAPs. The difference in effect was not statistically significant and in any event could be due to a cohort effect. The only way to determine if the FGA/SGA distinction is important here would be to conduct head-to-head trials of FGA-LAIs vs SGA-LAIs. It is likely that some studies included in this analysis systematically excluded patients who were expected to have poor adherence. If this is true, then the results should not be generalized to these patients and do not refute the possibility that LAIs may be superior to OAPs in this important group.

Funding

National Institute of Mental Health Advanced Center for Services and Intervention Research; the Zucker Hillside Hospital (P30MH090590).

Supplementary Material

Supplementary material is available at <http://schizophreniabulletin.oxfordjournals.org>.

Acknowledgments

We thank Stanley Ng, BS and Dr Vishesh Agarwal for help with the literature search and data abstraction, and Dr Jianping Zhang for the translation of Chinese article. We thank the following authors and pharmaceutical companies for providing additional, unpublished data: Drs Celso Arango, Igor Bombin, Wolfgang Gaebel, Nicholas A. Keks, Ichiro Kusumi, Andley Potapov, Robert Rosenheck, Nina Schooler, and Janssen Japan. Conflict of Interest: Dr Kishimoto has received consultant fees from Otsuka, Pfizer, Dainippon Sumitomo, and speaker's honoraria from Banyu, Eli Lilly, Dainippon Sumitomo, Janssen, Novartis, Otsuka, and Pfizer. He has received grant support from the Byoutaitaisyakenkyukai Fellowship (Fellowship of Astellas Foundation of Research on Metabolic Disorders), and Eli Lilly Fellowship for Clinical Psychopharmacology. Dr Robenzadeh has nothing to disclose. Dr C Leucht is SL's spouse, therefore the same conflicts of interest apply. She declares no additional conflicts of interest. Dr S Leucht received speaker/consultancy/advisory board honoraria from SanofiAventis, BMS, EliLilly, Essex Pharma, AstraZeneca, Alkermes, GlaxoSmithKline, Janssen/Johnson and Johnson, Lundbeck, Medavante, and Pfizer. He has received support for research from SanofiAventis and EliLilly. Dr Watanabe has been a consultant or has been received speaker/manuscript honoraria and research supports from Astellas, Dainippon Sumitomo, Eli Lilly, Glaxosmithkline, Janssen, Kyowa Hakko Kirin, Meiji Yakuin, Mochida, Otsuka, Pfizer, and Shionogi. Dr Mimura has received grants, or consultant fees from Eisai, Astellas Pharma, GlaxoSmithKline and Meiji, and received speaker's honoraria from Astellas Pharma, Dainippon Sumitomo Pharma, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, Meiji, Otsuka Pharmaceutical, Pfizer, and Yoshitomyakuhin. Dr Borenstein is founder of Biostat Inc, New Jersey, USA. He has received grants from NIH and IES to develop software for meta analysis, and has a commercial interest in the software Comprehensive Meta-Analysis. Dr Kane has been a consultant to Alkermes, Amgen, Astra-Zeneca, Janssen, Pfizer, Eli Lilly, Bristol-Myers Squibb, Dainippon Sumitomo/Sepracor/Sunovion, Johnson & Johnson, Otsuka, Pierre Fabre,

Vanda, Proteus, Takeda, Targacept, IntraCellular Therapies, Merck, Lundbeck, Novartis, Roche, Rules Based Medicine, Sunovion, and has received honoraria for lectures from Otsuka, Eli Lilly, Esai, Boehringer-Ingelheim, Bristol-Myers Squibb, Merck, and Janssen. He is a shareholder of MedAvante. He has received grant support from The National Institute of Mental Health. Dr Correll has been a consultant and/or advisor to or has received honoraria from Actelion, Alexza, AstraZeneca, Biotis, Boehringer-Ingelheim, Bristol-Myers Squibb, Cephalon, Desitin, Eli Lilly, Hofmann-La Roche, IntraCellular Therapies, Ortho-McNeill/Janssen/J&J, MedAvante, Merck, Novartis, Otsuka, Pfizer, ProPhase, and Sepracor/Sunovion. He has received grant support from the Feinstein Institute for Medical Research, the National Institute of Mental Health (NIMH), and the National Alliance for Research in Schizophrenia and Depression (NARSAD) and Ortho-McNeill/Janssen/J&J. Contributors: T. Kishimoto contributed to designing the study, literature search, data extraction/entering, statistical analysis, and writing the report. A. Robenzadeh contributed to literature search, data extraction/entering, and writing the report. C. Leucht contributed to designing the study, literature search, data extracting, statistical analysis, and writing the report. S. Leucht contributed to designing the study, data extracting, statistical analysis, and writing the report. K. Watanabe and M. Mimura contributed to designing the study and writing the report. M. Borenstein contributed to designing the study, statistical analysis, and writing the report. J. Kane contributed to designing the study and writing the report. C. Correll contributed to designing the study, quality assessment of studies, data extraction, statistical analysis, and writing the report.

References

1. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. *Biol Psychiatry*. 2001;50:884–897.
2. van Haren NE, Hulshoff Pol HE, Schnack HG, et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. *Neuropsychopharmacology*. 2007;32:2057–2066.
3. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. *Arch Gen Psychiatry*. 1999;56:241–247.
4. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. *Am J Psychiatry*. 2003;160:1209–1222.
5. Leucht S, Arbtter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. *Mol Psychiatry*. 2009;14:429–447.

6. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. *Lancet*. 2012;379:2063–2071.
7. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? *Am J Psychiatry*. 2002;159:103–108.
8. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. *Psychiatr Serv*. 2007;58:1187–1192.
9. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. *Br J Psychiatry Suppl*. 2009;52:S63–S67.
10. Waddell L, Taylor M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. *Br J Psychiatry Suppl*. 2009;52:S43–S50.
11. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia—a critical systematic review and meta-analysis of randomised long-term trials. *Schizophr Res*. 2011;127:83–92.
12. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. *N Engl J Med*. 2011;364:842–851.
13. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. *Am J Psychiatry*. 2010;167:181–189.
14. Macfadden W, Ma YW, Thomas Haskins J, Bossie CA, Alphas L. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. *Psychiatry*. 2010;73:23–31.
15. Schooler NR, Buckley PF, Mintz J, et al. PROACTIVE: initial results of an RCT comparing long-acting injectable risperidone to 2nd generation oral antipsychotics. *American College of Neuropsychopharmacology 50th annual meeting*. Kona, Hawaii; 2011.
16. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177–188.
18. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. *Am J Psychiatry*. 2004;161:1–56.
19. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. *J Clin Psychiatry*. 2003;64:663–667.
20. Foster P. Neuroleptic equivalence. *Pharmaceut J*. 1989;243:431–432.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315:629–634.
22. Li R, Zhang M, Shi S. The effect of haloperidol decanoate on negative and positive symptoms of schizophrenia. *Chin J Nerv Mental Dis*. 1996;22:9–12.
23. Bai YM, Chen TT, Chen JY, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. *J Clin Psychiatry*. 2007;68:1218–1225.
24. Arango C, Bombín I, González-Salvador T, García-Cabeza I, Bobes J. Randomised clinical trial comparing oral versus depot formulations of zuclopentixol in patients with schizophrenia and previous violence. *Eur Psychiatry*. 2006;21:34–40.

25. del Giudice J, Clark WG, Gocka EF. Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. *Psychosomatics*. 1975;16:32–36.
26. Falloon I, Watt DC, Shepherd M. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. *Psychol Med*. 1978;8:59–70.
27. Rifkin A, Quitkin F, Rabiner CJ, Klein DF. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. *Arch Gen Psychiatry*. 1977;34:43–47.
28. Leucht S, Corves C, Arbtter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet*. 2009;373:31–41.
29. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics [published online ahead of print November 29, 2011]. *Mol Psychiatry*. doi:10.1038/mp.2011.143.
30. Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. *BMJ*. 2006;333:224.
31. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. *Am J Psychiatry*. 2011;168:603–609.
32. Grimaldi-Bensouda L, Rouillon F, Astruc B, et al. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). *Schizophr Res*. 2012;134:187–194.
33. Lambert T, Olivares JM, Peuskens J, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. *Ann Gen Psychiatry*. 2011;10:10.
34. Peng X, Ascher-Svanum H, Faries D, Conley RR, Schuh KJ. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. *Clinicoecon Outcomes Res*. 2011;3:9–14.
35. Haddad PM, Tiihonen J, Haukka J, Taylor M, Patel MX, Korhonen P. The place of observational studies in assessing the effectiveness of depot antipsychotics. *Schizophr Res*. 2011;131:260–261.
36. Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. *Dialogues Clin Neurosci*. 2011;13:155–172.
37. A study of the efficacy and safety of long-acting injectable risperidone and risperidone tablets in patients with schizophrenia; Clinical Trials.gov Identifier NCT00240708. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=409&filename=CR004945_CSR.pdf. Accessed March 1, 2012.
38. Kamijima K, Ishigooka J, Komada Y. Comparison study between risperidone long-acting injectable and risperidone tablets in patients with schizophrenia. *Jpn J Clin Psychopharmacol*. 2009;12:1199–1222.
39. Silvestri S, Seeman MV, Negrete JC, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. *Psychopharmacology*. 2000;152:174–180.
40. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. *J Neurosci*. 2007;27:2979–2986.
41. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. *Biol Psychiatry*. 2008;64:145–152.
42. Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S. “Extended” antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2011;72:1042–1048.
43. Schooler NR, Levine J, Severe JB, et al. Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. *Arch Gen Psychiatry*. 1980;37:16–24.
44. An open-label randomized trial comparing Risperdal* Consta* with oral antipsychotic care in the treatment of early psychosis; Clinical Trials.gov Identifier NCT00246259. http://download.veritasmedicine.com/PDF/CR005959_CSR_synopsis.pdf. Accessed March 1, 2012.
45. Crawford R, Forrest A. Controlled trial of depot fluphenazine in out-patient schizophrenics. *Br J Psychiatry*. 1974;124:385–391.
46. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. *Arch Gen Psychiatry*. 1979;36:1283–1294.
47. Barnes TR, Milavic G, Curson DA, Platt SD. Use of the Social Behaviour Assessment Schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: pimozide versus fluphenazine. *Soc Psychiatry*. 1983;18:193–199.
48. Kaneno S, Ohkuma T, Yamashita I, et al. A double blind comparative study on the efficacy and safety of fluphenazine decanoate (SQ10, 733) and oral haloperidol in the treatment of schizophrenic patients. *Rinsho Hyoka (clinical evaluation)*. 1991;19:15–45.
49. Glick ID, Marder SR. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. *J Clin Psychiatry*. 2005;66:638–641.
50. Detke HC, Weiden PJ, Llorca P-M, Choukour M, Watson SB, Brunner E, Ascher-Svanum H. Open-label comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized study in outpatients with schizophrenia. NCDEU 51st annual meeting. Boca Raton, FL; 2011.
51. Keks NA, Ingham M, Khan A, Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. *Br J Psychiatry*. 2007;191:131–139.
52. Potapov A, Eduard T, Sergey M. Response, remission and relapse during the long-term treatment of schizophrenia patients with long-acting injectable risperidone versus olanzapine. *Int J Neuropsychopharmacol*. 2008;11:158–158.
53. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. *Neuropsychopharmacology*. 2010;35:2367–2377.